Postmenopausal women between 50 and 70 years of age without climacteric symptoms with either osteopenia or osteoporosis should be evaluated with regard to their breast cancer risk and considered for treatment with raloxifene within the framework of its contraindications and precautions.

No abstract

No abstract

While urogenital estrogen deficiency has been well investigated in recently perimenopausal or menopausal women, there is a lack of findings referring to elderly women. In addition women avoid discussing symptoms of vaginal atrophy with doctors during consultations. Local estrogen use is the most effective therapy to avoid progressive vaginal atrophy. There is a wide range of nourishing and lubricating preparations if the use of estrogen is to be avoided.

No abstract